Congenital Diarrheal Disorder (CDD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Congenital diarrheal disorders (CDDs) are a group of inherited enteropathies that typically manifest themselves in childhood. Despite their different outcomes, most CDDs have a similar clinical presentation. In most cases, appropriate therapy must be started immediately to prevent dehydration and long-term, and sometimes life-threatening, complications. Milder forms of CDDs, with a less severe clinical picture that remain undiagnosed until later ages, have been described. The less severe outcome may be due to a milder effect of disease gene mutations. Types of CDDs are more common in some ethnic groups due to consanguineous marriages or founder effects such as congenital lactase deficiency (CLD), lysinuric protein intolerance, or sucrose isomaltase deficiency. IL10RA was the most commonly detected pathogenic variant.
Congenital chloride diarrhea and
Schwachman–Diamond syndrome were leading causes of CDDs with 68% and 12%,
respectively, among the neonatal patients.
The competitive
landscape of Congenital Diarrheal Disorder (CDD) includes country-specific
approved and pipeline therapies. Any asset/product-specific designation,
review, and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Congenital
Diarrheal Disorder (CDD) across 8 MM market from the center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Congenital
Diarrheal Disorder (CDD) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Comments
Post a Comment